Metraipolis › archive › dc_cf43298b8ffd
Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers — Europe PMC PMID:42745921
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42745921
- DOI
- 10.3389/fimmu.2026.1925859
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-16T07:06:31.593Z
- SHA-256 of the archived text
e4ed9a892fafe27a4b8cbb6d8a2d6040595a916114e1a47fb2f357d87f2309b9- Stable URL of this page
https://metraipolis.com/documento/dc_cf43298b8ffd
How to cite
Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers — Europe PMC PMID:42745921 — Europe PMC (en), https://europepmc.org/article/MED/42745921 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cf43298b8ffd (Metraipolis archive dc_cf43298b8ffd, sha256 e4ed9a892fafe27a4b8cbb6d8a2d6040595a916114e1a47fb2f357d87f2309b9)
BibTeX
@misc{dccf43298b8ffd,
title = {Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers — Europe PMC PMID:42745921},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42745921},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cf43298b8ffd; sha256 e4ed9a892fafe27a4b8cbb6d8a2d6040595a916114e1a47fb2f357d87f2309b9},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42745921. Agents can read the archived copy with the MCP tool read_document.